Mutations of the N-ras oncogene and p53 tumor suppressor mia for point mutations of both the N-ras and p53 genes, After obtaining informed consent, mononuclear cells were
isolated from bone marrow samples from 44 patients with various types of MDS, nine cases with refractory anemia (RA), one case with primary acquired sideroblastic anemia (PASA), three cases with chronic myelomonocytic leukemia (CMMoL), Introduction eight cases with RA with excess of blasts (RAEB), one case with RAEB in transformation (RAEB-t) and 22 cases with MDSMyelodysplastic syndrome (MDS) is a stem cell disorder derived leukemia. The diagnosis of MDS was made according characterized by tri-lineage dysplasia of peripheral blood and to the French-American-British (FAB) classification. Samples bone marrow cells and ineffective hematopoiesis. The disease were taken at the time of diagnosis. In three cases, DNA was eventually develops into acute leukemia by the accumulation analyzed at different time-points during the course of the of heterogeneous mutations of oncogenes and tumor supdisease. Human leukemic cell line cells with known ras pressor genes. However, the order in which gene alterations and/or p53 gene mutations served as positive controls. occur during the course of disease progression is still not elucidated. Some gene alterations, especially chimeric gene formations, appear in association with chromosomal abnor-PCR malities, and others do not. The most common molecular abnormality in MDS is activation of the Ras proto-oncogenes, Point mutations were sought in exons 1 and 2 of the N-ras which is found in approximately 3-40% of patients. [1] [2] [3] [4] [5] gene and exons 5-9 of the p53 gene using PCR amplification Although the gene mutation appears at early as well as late with 50 ng of DNA samples and 10 pmol of the following stage of leukemic progression, it is suggested to be a predicprimer pairs: 5Ј-GACTGAGTACAAACTGGTGG-3Ј and 5Ј-tive factor for malignant transformation in the future.
2,5,6 The GGGCCTCACCTCTATGGTG-3Ј for exon 1 of N-ras; 5Ј-ras genes encode small G-proteins, which play an important GATTCTTACAGAAAACAAGT-3Ј and 5Ј-GTAGAGGTTAATrole in the signal transduction from receptor tyrosine kinases, ATCCGCAA-3Ј for exon 2 of N-ras; 5Ј-TTCCTCTTCCTACAGand acquire transforming activities in association with point TACTC-3Ј and 5Ј-GCAAATTTCCTTCCACTCGG-3Ј for exon 5 mutations of a single nucleotide within the region encoding of p53; 5Ј-ACCATGAGCGCTGCTCAGAT-3Ј and 5Ј-the GTP-binding portion of the protein. On the other hand, AGTTGCAAACCAGACCTCAG-3Ј for exon 6 of p53; 5Ј-the p53 tumor suppressor gene mutations are detected in 10-GTGTTATCTCCTAGGTTGGC-3Ј and 5Ј-CAAGTGGCT-15% of advanced MDS 7-9 and are preferentially associated CCTGACCTGGA-3Ј for exon 7 of p53; 5Ј-CCTATCCTGAGTwith 17p-. p53 protein acts as a controller of G1 checkpoint AGTGGTAA-3Ј and 5Ј-CCAAGACTTAGTACCTGAAG-3Ј for through its transactivation ability and the loss of normal p53 exons 8 and 9 of p53, respectively. The PCR program was 30 function by the point mutations in the highly conserved region cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 1 min, incorpoof the coding sequence, which interacts with DNA, is specurating ␣ 32 P dCTP (Amersham, Bucks, UK). lated to cause tumorigenesis.
To provide a new insight into the mechanism of pathogenesis in MDS, we simultaneously analyzed DNAs from 22
SSCP analysis and direct sequencing patients with MDS and 22 patients with MDS-derived leuke-
The FastSystem (Pharmacia, Uppsala, Sweden) was used in semiautomated SSCP analysis. The PCR products were the standard method. The PCR fragments, which showed mutations in exons 5 and 8. The other one was observed in one case with RAEB. All mutations were missense mutations shifted bands by SSCP analysis, were directly sequenced using 5 pmol of the same primers as those used in SSCP analysis as shown in Table 2 . The data of chromosomal studies were not available for patient 3, but other cases did not show and the Sequenase PCR Product Sequencing Kit (Amersham), according to the manufacturer's instructions. deletions of 17p, on which the p53 gene is mapped. The germ line bands were detected in all cases both with SSCP and sequencing.
No cases showed the coexistence of both the N-ras and Results p53 gene alterations, indicating no cooperative effects of both genes on the development or leukemic transformation of Firstly, we examined DNAs from 44 cases with MDS or MDSderived leukemia for the N-ras gene mutations in exons 1 and MDS. 2 by SSCP/direct sequencing. Heterozygous activating mutations were observed in two cases with MDS-derived leukemia (4.4%), in which both the mutated and normal wildDiscussion type alleles were detected (Table 1) . In one case, involvement of the first nucleotide in codon 12 of the N-ras gene, resulting This is the first report of simultaneous analysis for mutations of both the N-ras and p53 genes with a large number of MDS in substitution of glycine by serine, was seen (Table 2 ). In the other case, the second nucleotide of the same codon was altpatients. We have detected in this study two activating dominant point mutations in the N-ras gene and five mutations in ered and codon 12 was changed to asparic acid. The latter patient initially presented with RAEB which developed into the conserved region of the p53 gene out of 44 cases with MDS and MDS-derived leukemia. It should be noted that acute leukemia 5 months later. At that time, the N-ras gene mutation was not detectable using SSCP. However, leukemic almost half the cases in this study were diagnosed as MDSderived leukemias. The incidence of the N-ras gene mutations cells 3 years later showed the mutation at codon 12. Therefore, the leukemic clone harboring the N-ras mutation was 4.4% and that of p53 was 9.1%. The prevalence of the N-ras mutations in MDS was reported within the range of 3-acquired growth advantage and became dominant by the mechanism of clonal evolution. The t(11;19)(q23;p13,1), 40% in the literature. [1] [2] [3] [4] [5] The incidence in our study seems not to be significantly low in comparison with that in recent causing the formation of the MLL/MEN chimeric gene, also appeared after leukemic transformation in this case. 10 reports, which was less than 10%.
4,5 We could not detect the N-ras gene mutations in cases with MDS at early stage. This To investigate the p53 gene mutations in the same samples, exons 5-9 were amplified and electrophoresed according to might be due to the low number of patients with RA, PASA, and CMMoL. Patient 2 obtained the N-ras mutation after leuthe SSCP protocol, because most of the mutations reported so far were located in this region. Five point mutations were kemic transformation, indicating the role of the gene mutation in clonal evolution after transformation, but not in progression found in four patients (Table 1) . Three mutations were localized within exon 5, one within exon 7, and one within of the disease. In contrast, patients who lost the leukemic clone with the N-ras mutations after developing overt leukeexon 8. The results were confirmed by sequencing the corresponding exons. Four mutations were detected in three cases mia were also reported. 6,11 Therefore, the role of the ras mutations during the course of MDS could differ in each case. with MDS-derived leukemia and patient 5 carried two distinct Table 2 Summary of mutation analysis in the N-ras and p53 genes Many other genes, including c-fms, NF1, Rb, p16, EVI-1
